Status:
COMPLETED
Curcumin-Piperine Supplementation in STEMI - SPICE STEMI Trial
Lead Sponsor:
Universitas Diponegoro
Collaborating Sponsors:
Dr. Kariadi Hospital Semarang, indonesia
Conditions:
ST Elevation Myocardial Infarction (STEMI)
Malondialdehyde
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study aims to evaluate whether supplementation with a combination of curcumin and piperine can help reduce inflammation and oxidative stress in patients who have experienced a heart attack called...
Detailed Description
This randomized, double-blind, placebo-controlled clinical trial investigates the effects of combined curcumin and piperine supplementation on systemic inflammation and oxidative stress in patients wi...
Eligibility Criteria
Inclusion
- Adults aged 18 to 80 years.
- Confirmed diagnosis of ST-Elevation Myocardial Infarction (STEMI). Symptom onset within 12 hours, or within 12 to 72 hours in cases with an indication for primary percutaneous coronary intervention (PPCI).
- Receiving standard-of-care medical therapy according to current guidelines, including:
- Dual antiplatelet therapy. Angiotensin-Converting Enzyme Inhibitors (ACE-i) or Angiotensin Receptor Blockers (ARBs).
- Statins. Beta-blockers.
Exclusion
- Regular prior use of curcumin supplementation.
- Hemodynamic instability or severe dyspnoea with clinical signs of congestion (elevated jugular venous pressure, pulmonary rales affecting \>1/3 of lung fields, hepatomegaly, ascites, or peripheral oedema).
- History of prior myocardial infarction, previous percutaneous coronary intervention, or coronary artery bypass graft surgery.
- Known hypersensitivity to curcumin or piperine.
- Active malignancy.
- Chronic infections (e.g., hepatitis, tuberculosis, or HIV).
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or rapidly declining renal function.
Key Trial Info
Start Date :
February 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07149961
Start Date
February 5 2025
End Date
May 20 2025
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitas Diponegoro
Semarang, Central Java, Indonesia, 50275